• Investors
  • News
  • Subscribe
Hit enter to search or ESC to close
Cardax, Inc. | CDXI
  • About Us
    • Corporate Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Company History
  • Astaxanthin
    • Overview
      • Astaxanthin Overview
      • History and Background
      • Safety
      • Mechanism of Action
      • Synthetic vs. Natural Astaxanthin
    • Research in Key Addressable Markets
      • Cardiovascular Disease
      • Metabolic Disease
      • Liver Disease
      • Arthritis
      • Aging
      • Coronavirus Disease 2019 (COVID-19)
    • Scientific Literature
  • Programs
    • Product Platform
    • Commercialization Strategy
    • ZanthoSyn®
    • CDX-101
    • CDX-301
    • CHASE Clinical Trial
    • Intellectual Property
  • Newsroom
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact Us
Cardax, Inc. | CDXI

Press Releases

Investor Relations
Investors
  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Profile
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

Cardax Pharmaceuticals Appoints Fred Pashkow, MD, as EVP/CMO

Oct 9, 2006
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9

    News / Events

    • Press Releases
    • Media Coverage
    • IR Calendar
    • Presentations
    • Email Alerts
    Subscribe to Receive Updates by E-Mail Cardax News Alerts

    Recent News

    • Cardax Announces Breakthrough Longevity Results with ZanthoSyn® in NIH-Funded StudyDecember 6, 2023
    • Cardax Refocuses on ZanthoSyn® Consumer Health BusinessAugust 31, 2021
    • Cardax Voluntarily Suspends SEC Reporting ObligationsAugust 11, 2021

    *These statements have not been evaluated by the Food and Drug Administration.
    This product is not intended to diagnose, treat, cure, or prevent any disease.

    © 2025 Cardax, Inc. | Disclaimer and Terms of Use | Accessibility Statement

    • About Us
      • Corporate Overview
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Company History
    • Astaxanthin
      • Overview
        • Astaxanthin Overview
        • History and Background
        • Safety
        • Mechanism of Action
        • Synthetic vs. Natural Astaxanthin
      • Research in Key Addressable Markets
      • Scientific Literature
    • Programs
      • Product Platform
      • Commercialization Strategy
      • ZanthoSyn®
      • CDX-101
      • CDX-301
      • CHASE Clinical Trial
      • Intellectual Property
    • Newsroom
    • Investors
      • Investor Overview
      • News / Events
      • Company Information
      • Financial Information
      • Stock Information
      • SEC Filings
      • Corporate Governance
    • Contact Us
    • Investors
    • News
    • Subscribe